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Abstract
Background: Hirano bodies are actin-rich cytoplasmic inclusions found predominantly in the brain in association
with a variety of conditions including aging and Alzheimer’s disease. The function of Hirano bodies in normal
aging and in progression of disease has not been extensively investigated due to a lack of experimental model
systems. We have developed a transgenic mouse model by expression of a gain-of-function actin cross-linking
protein mutant.
Results: We used the Cre/loxP system to permit tissue specific expression of Hirano bodies, and employed the
murine Thy 1 promoter to drive expression of Cre recombinase in the brain. Hirano bodies were observed in the
cerebral cortex and hippocampus of homozygous double transgenic 6 month old mice containing Cre. The Hirano
bodies were eosinophilic rods, and also exhibited the paracrystalline F-actin filament organization that is
characteristic of these inclusions. Mice with Hirano bodies appear healthy and fertile, but exhibited some
alterations in both short-term and long-term synaptic plasticity, including paired-pulse depression rather than
facilitation, and decreased magnitude of early LTP.
Conclusions: Hirano bodies are not lethal and appear to have little or no effect on histology and tissue
organization. Hirano bodies do modulate synaptic plasticity and exert clearly discernable effects on LTP and paired-
pulse paradigms. This model system will allow us to investigate the impact of Hirano bodies in vivo, the pathways
for formation and degradation of Hirano bodies, and whether Hirano bodies promote or modulate development of
pathology and disease progression.
Background
Hirano bodies are cytoplasmic, eosinophilic, rod-shaped
inclusions that were initially described in patients with
amyotrophic lateral sclerosis or Parkinsonism-dementia
complex on Guam [1]. Hirano bodies are paracrystalline
and are composed of 8-10 nm filaments with 10-12 nm
spacing in longitudinal section, or a herringbone pattern
in an oblique section [2-4]. Hirano bodies contain F-
actin, actin-associated proteins such as tropomyosin,
vinculin, and cofilin [5-8], as well as microtubule-asso-
ciated proteins including tau [9,10]. They also contain a
number of other components including a wide variety of
growth factors, enzymes, and transcriptional regulators
including inducible nitric oxide synthase [11], FAC1
[12], and the cytoplasmic fragment of the amyloid pre-
cursor protein [13,14]. These inclusions have been
found predominantly in dendrites and cell bodies of hip-
pocampal pyramidal neurons of the brain under various
pathological conditions including Alzheimer’s disease
(AD), Amyotrophic Lateral Sclerosis (ALS), and Parkin-
son’s disease (PD) as well as in normal aged individuals
[15,16]. They have also been observed for human and
animal pathological material in the cerebral cortex, cere-
bellum, Purkinje cells, peripheral nerves, oligodendroglia
and Schwann cells, astrocytoma, and muscle cells [4].
Further, some model APP transgenic mice accumulate
cytoplasmic aggregations structurally similar to Hirano
bodies [17-19], though none of these studies focused on
Hirano bodies. The physiological effect of Hirano bodies
is not understood, since nearly all prior reports on Hir-
ano bodies have been performed on post-mortem sam-
ples by immunohistochemistry and electron microscopy.
We have developed cell models for the formation of
Hirano bodies in the cellular slime mold Dictyostelium
discoideum as well as in a variety of cultured cell models
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such as fibroblasts, epithelial cells, glial cells, neuronal
cell lines, and primary neurons by expressing a trun-
cated form (C-terminal amino acids 124-295) of the 34
kDa F-actin bundling protein [14,20-23]. The model
Hirano bodies closely mimic authentic Hirano bodies in
the brain both in composition, and in ultrastructural
characteristics [14,22,23]. Specifically, these model Hir-
ano bodies are paracrystalline filament arrays that con-
tain actin, actin binding proteins, tau, and C-terminal
fragment(s) of amyloid precursor protein as previously
reported in human and animal tissues.
To understand the physiological function and effect of
Hirano bodies in aging and disease progression, we have
used the Cre/loxP system to generate a transgenic
mouse model expressing CT-GFP flanked by loxP sites
at the Rosa26 locus [24-26]. In this study, we have con-
firmed that CT-GFP was expressed in the brain from
day 14.5 following Thy1-Cre recombination, consistent
with previous characterization of this promoter [27].
However, the formation of Hirano bodies in the hippo-
campus was first observed in 6 month homozygous dou-
ble transgenic mice (R26CT+/+;Cre+). The presence of
these inclusions was confirmed using light and electron
microscopy as eosinophilic rod-shaped structures, and
as paracrystalline F-actin structures consisting of 8-10
nm filaments with 10-12 nm spacing. This mouse model
for Hirano bodies may provide a valuable tool to study
the effects of Hirano bodies in human disease and aging.
Methods
Mice
To generate inducible R26CT transgenic mice expres-
sing CT-GFP, a targeting vector was constructed by
inserting a SA-loxP-bgeo-pA-STOP-loxP-CT-GFP-pA
CT-GFP inducible cassette into the XbaI site of the vec-
tor pROSA26-1, which contains a 5-kb genomic frag-
ment of Rosa26 locus for homologous recombination
and a diphtheria toxin (DTA) expression cassette for
negative selection [25]. The construct CT-GFP inducible
cassette was generated from plasmid pSAbgeo [28] by
inserting a loxP site into the HindIII site and ligation
with STOP [29] and a loxP-CT-GFP-pA fragment. A
CT-GFP-pA fragment was generated by PCR in which
the CT fragment (amino acids 124-295) encoding 34
kDa actin bundling protein from Dictyostelium was sub-
cloned into the BamHI site of the pEGFP-N1 (Clontech,
Palo Alto, CA) at the carboxyl-terminus to express a
fusion protein of CT with GFP (CT-GFP-pA). The tar-
geting vector was linearized and introduced into a
C57BL/6J mouse ES cell line by electroporation at the
Medical College of Georgia Transgenic and Knockout
Mouse Core Facility at Augusta, Georgia. Correctly tar-
geted cell lines were screened with PCR and Southern
Blot with a 5’ flanking probe, both of which have been
described previously [25]. For transgene genotyping in
ES cells, we used the following primers (Figure 1): Pa
(ROSA26 forward - 5’ flanking) 5’-CCTAAAGAA-
GAGGCTGTGCTTTGG-3’; Pb (Rosa SA reverse) 5’-
CATCAAGGAAACCC TGGACTACTG-3’; Pc (GFP
forward) 5’-GCACCATCTTCTTCAAGGACGAC -3’;
Pd (ROSA26 reverse - 3’ flanking) 5’-CCGACAAAACC-
GAAAATCTGTG-3’. This genotyping PCR amplifies a
1.2 Kb band with Pa and Pb in 5’ junction, as well as a
850 bp band with Pc and Pd in 3’ junction to confirm
homologous recombination in ROSA 26 locus using
DNA isolated from ES cells. The targeted ES cells were
microinjected into blastocysts to generate chimeric
mice. The R26CT colony was maintained by PCR geno-
typing, which can distinguish between the endogenous
and transgenic Rosa26 allele. R26CT colony was main-
tained on C57BL/6J genetic background.
To generate double transgenic mice for the formation
of Hirano bodies in the brain, R26CT mice were mated
to Thy1-Cre mice (line 703; Dr. Valerie Wallace, Uni-
versity of Ottawa) that express CRE recombinase
broadly in neural and non-neural tissues under control
of a modified Thy1 promoter [27]. For R26CT and Cre
genotyping, we used the following primers: P1 (R26-
1GTFOR) 5’-TTGGAGGCAGGAAGCACTTG -3’; P2
(ROSASAREV) 5’-CATCAAGGAAACCC TGGAC-
TACTG-3’; and P3 (R26-1GTREV) 5’-CCGACAAAACC
GAAAATCTGTG-3’. This genotyping PCR amplifies a
230 bp band from the R26CT allele and a 369 bp band
from the wild type Rosa26 allele. To check for Cre, the
primers were: Cre forward 5’-CCAGGCCTTTTCTGAG-
CATACC-3’ and Cre reverse 5’-CAACACCATTTT
TTCTGACCCG-3’. The PCR product is 641 bp. The
day of the vaginal plug was designated as E0.5. All
experiments were carried out with the approval of the
University of Georgia institutional animal care
committee.
Immunofluorescence labeling
Immunofluorescence microscopy was performed follow-
ing methods described previously [30]. Mice from post-
natal 0 to 9 month were anesthetized and whole brains
were dissected for immunostaining and histology. For
cryosection, dissected whole brains were fixed with 4%
paraformaldehyde overnight, followed by cryoprotection
in 30% sucrose and embedding in OCT (Optical Cutting
Temperature, Tissue-Tek 4583) and storage in liquid
nitrogen. Sections (10 μm) were cut from frozen tissue
using a cryostat (Leica) and electrostatically attached to
Super-frost glass slides (Fisher Scientific, Pittsburgh,
PA). Sections were blocked for 1 hour in 4% milk
(NDM)/TST buffer (10 mM Tris-HCl, pH 7.4; 150 mM
NaCl; 0.1% Tween20). They were incubated in primary
antibody at room temperature overnight. The slides
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Figure 1 Targeting strategy of CT-GFP inducible R26CT mouse. (A). Top: The structure of targeting vector containing a loxP-flanked (bgeo/
stop) cassette with CT-GFP pA target gene. A pROSA26-1 plasmid contains ROSA26 genomic sequences and a diphtheria toxin gene (PGK-DTA)
to increase rate of homologous recombination and negative selection in ES cells, respectively. Middle: the genomic organization of endogenous
Rosa26 locus. The structure of the targeted Rosa26 allele (R26CT) which expresses b-galactosidase and a neomycin resistance cassette fusion
gene mRNA. Bottom: Cre-mediated excision of targeted R26CT allele to transcribe CT-GFP mRNA. loxP, solid arrow head; bgeo, a fusiongene of
b-galactosidase and neomycin (Neo) resistant gene;. pA, polyA signal; STOP, a transcription stop sequence. (B) Southern Blot analysis of genomic
DNA prepared from Neo resistant ES cell lines. It was digested with EcoRV and hybridized with a32P-labeled 5’ probe indicated in A. The 3.8 kbp
EcoRV fragment indicates the targeted R26CT allele and the 11 kbp EcoRV fragment represents wild type Rosa26 allele. (C) PCR screening for the
targeting event. A set of primers shown in A were used to amplify 1.2 kbp (Pa and Pb) and 0.85 kbp (Pc and Pd) size fragments from the R26CT
allele, but not wild type Rosa26 allele. (D) Southern Blot analysis of genomic DNA prepared from heterozygous R26CT and wild type mice. After
EcoRV digestions, the 5’ probe was used the same as mentioned in A. (E) PCR screening for the targeting event to amplify 1.2 kbp band from
the R26CT allele.
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were washed three times in 4% milk/TST buffer for 5
min each, followed by 1 hour incubation with biotiny-
lated secondary goat anti-rabbit antibody (Jackson
Immunoresearch Laboratories, West Grove, PA; 1:100
dilution). After washing as above, they were incubated
in Cy2 conjugated streptavidin (Jackson Immunore-
search Laboratories, West Grove, PA; 1:200 dilution) for
30 min. Signal was detected by either standard fluores-
cence microscopy or laser scanning confocal micro-
scopy. The following antibodies and dilution were used:
polyclonal rabbit anti-GFP antibody (Invitrogen, Carls-
bad, CA; 1:100 dilution) or polyclonal rabbit anti-34
kDa (1:50 dilution) and Phalloidin-TRITC (Sigma-
Aldrich Chemical Co., St. Louis, MO; 1:40 dilution).
Histology
H and E staining was performed as previously described
with slight modification [31]. For paraffin sections, dis-
sected brains were fixed with 4% paraformaldehyde at 4°
C overnight, dehydrated in a graded series of 50, 75, 90,
96 and 100% ethanol, equilibrated with xylene,
embedded in paraffin and sectioned on a sliding micro-
tome at a thickness of 5-10 μm. After dewaxing with
xylene, sections were stained with Mayer’s hematoxylin
(Sigma-Aldrich Chemical Co., St. Louis, MO) and eosin
(Sigma-Aldrich Chemical Co., St. Louis, MO) solution
and mounted on slides.
Transmission Electron Microscopy
TEM was performed as previously described with slight
modification [17]. Mice from postnatal 0 to 6 months
were anesthetized, and whole brains were dissected to
separate hippocampus from cortex and thalamus. Hip-
pocampal tissue blocks were fixed by immersion with
4% paraformaldehyde/2% glutaraldehyde in 0.1 M caco-
dylate buffer, pH 7.4 overnight, and then postfixed in
1% osmium tetroxide (OsO4) for 2 hours. After serial
dehydration in ethyl alcohol, tissues were embedded in
Epon (Embed-812; Electron Microscope science, PA,
USA). Semithin sections were stained with 1% toluidin
blue in 1% sodium tetraborate. Ultrathin sections were
collected on nickel grids, and then counterstained with
uranyl acetate for 30 min and lead citrate for 5 min at
room temperature. Samples were observed with a JEOL
100CX with an accelerating voltage of 80 kV.
Western blot analysis
Western analysis was performed as described previously
with slight modification [19]. The brains from transgenic
mice were dissected, and hippocampi were homogenized
in 5 volumes of lysis buffer containing 1% triton-X 100,
0.1% SDS, 0.5% deoxycholic acid, 20 mM Tris-Cl pH
7.5, 10% glycerol, 0.5 M EDTA, 2 mM PMSF (phenyl-
methyl sulfonyl fluoride), leupeptin (1 μg/ml), pepstatin
(1 μg/ml), and aprotinin (1 μg/ml). Cell debris was sepa-
rated from total homogenate by centrifugation at 14,000
g for 30 min at 4°C. Supernatant was stored at -80°C
until used. Protein concentrations of the supernatants
were determined by Bradford protein assay (Bio-Rad,
Richmond, CA, USA) using BSA as a standard. For
immunoblot analysis, tissue samples were loaded with
100 μg of protein per lane and separated on 12% SDS-
polyacrylamide gels. Blots were probed using anti-34
kDa (B2C) mouse monoclonal antibody at a 1:5000 dilu-
tion, anti-a Tubulin mouse antibody (Sigma-Aldrich
Chemical Co., St. Louis, MO) at a 1:1000 dilution, and
anti-MAP LC3 (N-20) goat antibody (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) at a 1:500 dilution.
The signals were detected by chemiluminescence (Pierce
Biotechnology, Rockford, IL).
Extracellular Electrophysiology and Quantification of
synaptic plasticity
Hippocampal slices were prepared from male homozy-
gous transgenic mice at 7 months of age (R26CT+/+ as
control and R26CT+/+;Cre+ as Hirano Body animals)
using an experimental protocol performed in compli-
ance with the University of Georgia Animal Care and
Use guidelines. All mice were anesthetized with
halothane prior to decapitation. The brain was removed
and submerged in ice-cold, oxygenated (95% O2/5%
CO2) dissection artificial cerebrospinal fluid (ACSF)
containing 120 mM NaCl, 3 mM KCl, 4 mM MgCl2, 1
mM NaH2PO4, 26 mM NaHCO3, and 10 mM glucose.
Horizontal brain slices were cut at a thickness of 400
μm, and the hippocampus dissected free. Slices were
perfused with room-temperature, oxygenated (95% O2/
5% CO2) standard ACSF containing 120 mM NaCl, 3
mM KCl, 1.5 mM MgCl2, 1 mM NaH2PO4, 2.5 mM
CaCl2, 26 mM NaHCO3, and 10 mM glucose at
approximately 1 ml/min. Slices recovered for one hour
at room temperature, and another hour at 30°C, the
temperature at which recordings were obtained. A bipo-
lar stimulating electrode (Kopf Instruments, Tujunga,
CA) was placed on the CA3 side of the stratum radia-
tum and an extracellular recording microelectrode (1.0
MΩ tungsten recording microelectrode, (World Preci-
sion Instruments, Sarasota, FL) was positioned in the
same layer in CA1.
Data were digitized at 10 kHz, low-pass filtered at 1
kHz, and analyzed with pCLAMP 9.2 software (Axon
Instruments, Sunnyvale, CA). The initial slope of the
population fEPSP was measured by fitting a straight line
to a 1 msec window immediately following the fiber vol-
ley. Stimulus-response curves were obtained at the
beginning of each experiment, with stimulus pulses con-
sisting of a single square wave of 270 μs duration deliv-
ered at 30, 40, 50, 60, 70, 85, 100, 120, 140, and 160 μA
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in the stratum radiatum once every 60 s (0.0167 Hz). To
begin baseline recording, the stimulation intensity was
adjusted to obtain a field EPSP of approximately 40-50%
of the maximum response, and paired-pulse responses
were measured from an average of five pairs of pulses
delivered at a 50 msec interval. For long-term potentia-
tion (LTP) experiments, synaptic responses were nor-
malized by dividing all fEPSP slopes by the average of
the 5 responses obtained from the 5 min immediately
prior to high-frequency stimulation (HFS). The HFS
protocol used to induce LTP in all experiments con-
sisted of 3 episodes of 100 Hz/1 sec stimulus trains
administered at 20 sec intertrain intervals. Planned com-
parisons between homozygous R26CT+/+ transgenic
mice as controls were made with R26CT+/+;Cre+ Hirano
Body mice at 30 minutes and 240 minutes post-HFS
using unpaired t-tests. Reported n-values (x(y)) indicate
the number of slices (x) and the number of animals (y)
assessed.
Results
Generation of R26CT transgenic mice
To generate a transgenic (Tg) mouse model of Hirano
bodies, we anticipated possible lethality and so devised a
strategy to target the broadly expressed and weak ROSA
promoter in embryonic stem cells, and employed CRE
technology to allow flexibility in control of tissue speci-
fic expression. We prepared a targeting vector, in which
the sequence encoding CT-GFP along with poly A was
inserted downstream of a floxed bgeo-pA-STOP cas-
sette, and introduced into the pROSA26-1 trap vector.
The pROSA26-1 trap vector contains ROSA26 genomic
sequences to permit homologous recombination and
also a PGK-DTA cassette (phosphoglycerate kinase-1
promoter and diphtheria toxin) for negative selection
(Figure 1A) [25]. The targeting vector was electropo-
rated into embryonic stem (ES) cells derived from strain
C57BL/6 and the targeted alleles were screened by
Southern blotting to determine homologous recombina-
tion (Figure 1A, B). To confirm homologous recombina-
tion of CT-GFP transgene within the ROSA26 locus, 5’
and 3’ flanking regions were amplified by PCR using
two primer sets at the same time (Figure 1A, C). The
targeted ES clones were injected into C57BL/6 blasto-
cysts to generate chimeric mice. By testing these chi-
meric animals for germ line transmission, we identified
4 founders (R26CT) out of 6 mice in which the CT-GFP
transgene was targeted into ROSA26 genomic regions as
determined by southern blot and PCR (Figure 1D, E).
Generation of R26CT+/-;Thy1-Cre+ double transgenic (DTg)
mice
To induce formation of Hirano bodies, we used the Cre/
loxP site specific recombination system [25,26] in which
the tissue specificity of expression for the recombina-
tion-activated dormant transgene is determined by the
promoter specificity of the Cre transgene. Thy1-Cre
transgenic mice induce a transgene with tissue-specifi-
city in the central and peripheral nerve systems includ-
ing neuronal tissues of the cerebral cortex and
hippocampus, and non-neuronal tissue [27]. R26CT
transgenic mice carrying CT-GFP transgene were mated
with Thy1-Cre (703 line) transgenic mice expressing the
Cre recombinase under the control of murine Thy1.2
regulatory elements. Homozygous R26CT (R26CT+/+;
Cre+) double transgenic mice were generated through
appropriate crosses between heterozygous R26CT
(R26CT+/-; Cre+) mice to increase the expression level
of the CT-GFP transgene. Transgene and Cre gene pre-
sence as well as copy number were determined by PCR
genotyping as described in Materials and Methods.
Expression of CT-GFP in the hippocampus at P0
Since Thy1-Cre reporter activity was observed in retina
and hippocampus at postnatal day 0 (P0) in Thy1-Cre;
ROSA transgenic mice [27], we asked whether double
transgenic mice express CT-GFP in the hippocampus at
P0. To assess transgene expression in hippocampus of
the brain, frozen sections of the brain prepared from
neonatal wild type, heterozygous, and homozygous
transgenic mice were stained with antibody to GFP to
enhance fluorescence from the transgene, and visualized
by fluorescence microscopy. CT-GFP transgene was
expressed in the hippocampus (Figure 2A), consistent
with prior characterization of the Thy1-Cre model [27].
The expression level of CT-GFP of homozygous DTg
mice was higher than that of heterozygous DTg mice
(Figure 2A). To confirm these results using a biochem-
ical approach, lysates of hippocampi of each genotype of
DTg mice were examined by western blot analysis with
anti-34 kDa (B2C) antibody (Figure 2B). Expression
levels of the transgene in homozygous DTg mice were
increased more than two times compared to that of het-
erozygous DTg mice. Therefore, the expression level of
CT-GFP protein is consistent with transgene copy num-
ber. Further, from 1 to 6 months of age, the level of
expression of the CT-GFP protein increased (Figure 2C).
It has been reported that the major component of
Hirano bodies is F-actin [5]. To examine whether CT-
GFP co-localizes with F-actin in the brain at P0, expres-
sion of CT-GFP in the hippocampus was examined by
immunohistochemistry using either anti-34 kDa anti-
body (Figure 3) or anti-GFP antibody (data not shown)
in combination with phalloidin to stain filamentous
actin. We confirmed that CT-GFP was not only predo-
minantly expressed in the hippocampus, but also largely
co-localized with F-actin in the hippocampal pyramidal
layer CA1, CA2, and CA3 regions. In addition, the
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expression level of CT-GFP was higher in CA3 as com-
pared to CA1 (Figure 3).
Formation of Hirano bodies in the hippocampus of 6
month homozygous DTg mice
In various human disorders and experimental animal
models, Hirano bodies have two major distinctive fea-
tures: first, eosinophilic rod-shaped cytoplasmic inclu-
sions that contain actin filaments [1,5]; and second,
lattice-like aggregates of parallel filaments [2,3]. These
features were utilized to test for formation of Hirano
bodies in our transgenic mice.
To determine whether model Hirano bodies are pre-
sent as indicated by the presence of eosinophic rod-like
aggregates and paracrystalline structure, we dissected
whole brains and performed H and E staining for histol-
ogy (Figure 4 and 5), and electron microscopy (Figure 6)
on the two hemispheres of brains from heterozygous
and homozygous transgenic mice. We did not detect the
formation of Hirano bodies in any heterozygous (R26CT
+/-; Cre+) transgenic mice (3, 6, 9 and 12 months of age;
n = 2 for each age), and in homozygous (R26CT+/+; Cre
+) transgenic mice (1 and 3 months of age; n = 2 for
each age; data not shown). By contrast, in homozygous
DTg mice 6 months of age, we observed eosinophilic
cytoplasmic inclusions adjacent to the perikaryon of pyr-
amidal cells in the hippocampus (Figure 5C, D). Eosino-
philic Hirano bodies were not observed in wild type
controls even as old as 24 months (data not shown).
Further, ultrastructural study showed that Hirano
bodies, under 1 μm in diameter, appeared to lie partially
within myelinated sheath. These paracrystalline inclu-
sions were composed of parallel filaments 8-10 nm in
diameter with 10-12 nm interspacing between filaments
consistent with previous studies (Figure 6) [2,32,33]. As
a control, we used H4 stable cells expressing CT-GFP
[14,22]. Hirano bodies were clearly seen in the cyto-
plasm without enclosed membrane (Figure 6A and 6B),
consistent with prior reports of model Hirano bodies in
cultured cells. Thus, Hirano bodies were observed both
Figure 2 Expression level of transgene CT-GFP in the brain of double transgenic R26CT allele. (A) Transgene expression in the
hippocampus of double transgenic R26CT mouse and wild type (WT) at P0. Heterozygous and homozygous double transgenic mice were
stained with anti-GFP antibody. (B,C) Homogenates of hippocampi of different double transgenic R26CT allele were analyzed by Western blot.
Expression of CT-GFP was correlated with transgene copy number, increased from 1 to 6 month of age. Major induction of autophagy as
indicated by accumulation of the modified form of LC3-I was not detected. Arrow indicates cytosolic LC3-I and arrow head represents an
autophagosome-associating form, LC3-II which is an autophagy marker.
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by H and E and by electron microscopy in homozygous
transgenic mice 6 months of age (n = 2 for both H and
E and electron microscopy), but not in heterozygous
transgenic mice 3, 6, 9, and 12 months of age. Further,
the Hirano bodies were observed both by electron
microscopy and by H and E staining only in animals
with Cre recombinase, and never in Cre- animals (Figure
5 and 6; data not shown).
The absence of Hirano bodies in heterozygous trans-
genic mice with a single copy of the transgene, and
delay in appearance of Hirano bodies until 6 months in
homozygous transgenic mice in vivo was surprising to
us, since formation of Hirano bodies was observed with
24 hours of induction of expression in cultured cell
models of Hirano bodies [14,20-22]. Formation of Hir-
ano bodies in homozygous double transgenic mice but
not in heterozygous double transgenic mice with only a
single copy of the transgene may be due to the low level
of expression in mice carrying a single copy of the
transgene (Figure 2B). This finding is consistent with
the observation that the Rosa26 promoter has been
characterized to be a ubiquitous promoter which is rela-
tively weak and displays a low level of transcription [34].
To understand why the formation of Hirano bodies is
delayed to 6 months in the homozygous double trans-
genic mice with two copies of the transgene, we per-
formed western blot analysis using hippocampi dissected
from homozygous DTg mice 1, 3, and 6 months of age
to determine their levels of expression of the 34 kDa
protein. Between 1 and 6 months, expression of CT-
GFP protein increased (Figure 2C), suggesting that the
accumulation of the CT-GFP protein could contribute
Figure 3 Expression of transgene CT-GFP in the hippocampus. Sections cut through brain of wild type (A-D) and R26CT allele (E-P) were
visualized by immunofluorescence at postnatal 0 (P0). Hirano bodies induced by CT-GFP protein are co-localized with phalloidin in the
pyramidal layer of hippocampus. Brain sections are stained with anti-34 kDa (green; A, E, I, M) to detect CT-GFP protein or with phalloidin TRITC-
conjugated (red; B, F, J, N) to detect F-actin, Hoechst 33342 (C, G, K, O) for nuclei, and merged images (D, H, L, P). (A-D) wild type. (E-H)
heterozygous R26CT+/-;Cre+. (I-P) homozygous R26CT+/+;Cre+. (M-P) Higher magnification of hippocampal cells in homozygous double transgenic
mice. Areas of co-localization appear yellow in the merged image. Scale bar = 100 μm (A-L), 20 μm (M-P).
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to modulation of the formation of Hirano bodies. Since
autophagy can contribute to the degradation of Hirano
bodies in cultured cells [23], we tested for induction of
autophagy in our Hirano body model mice. We used
Western blotting to examine the accumulation of two
forms of the autophagy protein termed LC3-1 and LC3-
II (Figure 2C). Increased autophagic activity is reflected
by the enhanced conversion of LC3-I to LC3-II [35].
Expression of LC3-II was not detected by 6 month (Fig-
ure 2C, arrow head). However, we found consistent
expression of cytosolic LC3-I protein in the brain (Fig-
ure 2C, arrow). While these findings do not rule out the
role of basal autophagy in control of the levels of Hirano
bodies in the brain, they do show that no major induc-
tion of autophagy is detectable in these mice.
Effects of Hirano body expression on hippocampal
structure and physiology
Both heterozygous and homozygous DTg mice were
viable and fertile (data not shown). To determine
whether the presence of Hirano bodies affected the num-
ber and organization of hippocampal pyramidal neurons,
we compared preparations from wild type and double
transgenic mice by H and E staining. There was no
difference in cell density or organization in the CA1,
CA2, or CA3 regions of the hippocampus among WT,
R26CT+/+; Cre+, and R26CT+/+; Cre- mice (Figure 4A-L).
In order to determine if the presence of Hirano Bodies
can impact neuronal function at 7 months of age, field
excitatory post-synaptic potentials (fEPSPs) were
recorded in the stratum radiatum layer as a measure of
synaptic function in the CA1 region of the hippocampal
formation. Although a tendency for the baseline fEPSPs
of Hirano body mice to be smaller than those recorded
from control mice was evident, the responses of these
groups were not significantly different at any of the
tested stimulus intensities (Figure 7A). We also investi-
gated the effect of a paired-pulse stimulus protocol in
which a second stimulus pulse (P2) was delivered 50
msec after the first pulse (P1, Figure 7B). Control
R26CT+/+ mice exhibited paired-pulse facilitation (P2/P1
ratio of 1.16 ± 0.09; n = 13(7)), consistent with the
expected responses from wild type mice [36]. Unexpect-
edly, a strong paired-pulse depression (P2/P1 ratio of
0.49 ± 0.03; n = 8(4)) was observed in the Hirano body
mice (**, p < 0.001, unpaired t-test).
Following the induction of long term potentiation
(LTP), the fEPSP slope at 30 minutes post-tetanus was
Figure 4 Histological analysis of 6 month adult brains. Serial sagital sections of brains from wild type and homozygous transgenic mice
were analyzed by hematoxylin and eosin (H and E) staining. (A-L) No differences in the pyramidal cell layer in the hippocampus (CA1, CA2, and
CA3) are discernable between wild type (A-D), R26CT+/+ (E-H), and R26CT+/+;Cre+ (I-L) transgenic mice at 6 months of age.
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increased 76 ± 10% in the hippocampal slices of control
mice (homozygous R26CT+/+; Cre-; n = 13(7)) as com-
pared to 37 ± 3% in transgenic mice (homozygous
R26CT+/+; Cre+; n = 8(4)), and this difference was statis-
tically significant (**, p < 0.01, unpaired t-test). However,
at 240 min post-tetanus the fEPSP slope was not signifi-
cantly different in transgenic Hirano body mice com-
pared to those of control mice (55 ± 12%, 49 ± 10%
respectively, Figure 8A,B).
Taken together, the electrophysiology results sug-
gest that Hirano bodies are not toxic, that baseline
synaptic function in the CA1 region of the hippocam-
pus is preserved in Hirano body mice, and that these
synapses can exhibit activity-dependent plasticity in
the form of late LTP measured up to four hours
post-tetanus. However, there are obvious differences
in more transient forms of synaptic plasticity from
those observed in the control mice. Notably, there is
a shift from facilitation to depression in the paired-
pulse assay during short-term plasticity, and a reduc-
tion in the magnitude of early LTP assessed 30 min-
utes post-tetanus during induction of long-term
plasticity. Studies of homozygous double transgenic
(R26CT+/+; Cre+) and control (R26CT+/+; Cre-) mice
at 18 months of age produced results comparable to
those observed at 7 months, but the short supply of
these aged mice severely limited these observations
(data not shown).
Figure 5 Detection of Hirano Bodies by H and E Staining. The rod-shaped eosinophilic inclusions were found in the vicinity of pyramidal
cells of hippocampus in homozygous double transgenic mice (C,D). Hirano bodies were not observed in wild type mice (A), or double
transgenic mice lacking Cre (B). Arrow heads indicate Hirano bodies. Scale bar = 20 μm.
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Figure 6 Paracrystalline structure of mouse model Hirano Bodies. Hemisphere brain was dissected by separating hippocampus from cortex
and thalamus. (A, B) Transmission electron microscope (TEM) images of the electron dense region in CT-GFP stable H4 human neuroglioma cells
show the composition, filamentous organization, and cross-hatched appearance of the inclusions. (C-J) TEM images of hippocampus in
homozygous double transgenic mice at 6 months reveal model Hirano bodies with characteristic structure and periodicity. The small size of
filamentous inclusions are enclosed by myelin sheath and resemble the ultrastructural definition of Hirano bodies reported in the hippocampus
of an Alzheimer’s patient. Scale bars: 500 nm (A, C, E, G), 200 nm (B, D, F, H), 50 nm (I), and 20 nm (J). White square box shows a filamentous
array that is magnified in the inset (B, D, F, and H).
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Figure 7 Synaptic fEPSP responses evoked and recorded in the s. radiatum layer of Hirano Body and control mice. Insets are averaged
fEPSP sweeps for both control and Hirano Body groups. The stimulus artifacts are truncated at 3 mV in the vertical axis, and the sweeps are 100
msec in duration in the horizontal axis. A) Stimulus-response curves for both Hirano Body (filled circles) and control mice (open circles) at the
indicated stimulus intensities. B) Paired-pulse fEPSP responses (50 msec isi). The open bar represents the control group (n = 13(7)); the filled bar
represents the Hirano body group (n = 8(4)). The paired-pulse ratios were determined by dividing the slope of the second pulse by that of the
first (**, p < 0.001, unpaired t-test). Error bars show mean ± SEM.
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Discussion
Our knowledge of Hirano bodies includes a careful
description of their structure, histology, and association
with a variety of conditions including normal aging and
neurodegenerative disease [4]. However, we have very
little information regarding the effect(s) of these struc-
tures on aging and disease progression in living cells. In
this report, a mouse model of Hirano bodies was
generated in order to permit investigation of Hirano
bodies within a multicellular vertebrate organism. The
authenticity of the Hirano bodies was verified by com-
parison to the hallmark properties reported consistently
in prior studies of Hirano bodies. Eosinophilic rod-
shaped inclusions were seen in the CA3 region of the
hippocampal pyramidal cell layer by H and E staining
(Figure 5) [1]. The CT-GFP was largely co-localized
Figure 8 Long-term Potentiation of the fEPSP responses from Hirano Body and Control Mice. A) Summary plot of normalized fEPSP slope
measurements evoked and recorded in the s. radiatum layer of the CA1 region. Open squares depict responses from the control group; closed
squares represent responses from the Hirano body group; HFS (3 × 100 Hz/1 sec) was administered at time = 30 min (arrow) to induce LTP. B)
Summary quantification of LTP magnitude at both 30 min post-HFS (early LTP) and 240 min post-HFS (late LTP). The open bars represent the
control group; the filled bars represent the Hirano body group (**, p < 0.01, unpaired t-test). Error bars show mean ± SEM.
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with rhodamine-phalloidin confirming the presence of a
high concentration of actin filaments (Figure 3) [5].
These structures were detected only in mice that con-
tain both the CT-GFP transgene and the CRE recombi-
nase, and were also enriched for the CT-GFP transgene
that we used to induce the model Hirano bodies (Figure
3). Finally, images from electron microscopy confirmed
the presence of paracrystalline structures with a filament
diameter of 8-10 nm and a center to center spacing of
10-12 nm that were surrounded by a myelin sheath.
These inclusions closely resemble the ultrastructural fea-
tures of Hirano bodies reported in cultured cells and in
the human hippocampus (Figure 6) [2,32,33]. Further,
the presence of Hirano bodies within myelinated fibers
is also consistent with prior reports [4,32]. These find-
ings demonstrate that the model Hirano bodies in this
transgenic mouse closely mimic the features of Hirano
bodies reported in humans and animal models.
While our results clearly demonstrate the presence of
model Hirano bodies in the hippocampus of the mice, a
number of interesting questions regarding the formation
of these structures remain to be addressed. First, the
formation of Hirano bodies was initially observed in
homozygous double transgenic mice (R26CT+/+;Cre+)
aged 6 months, but not in younger mice of the same
genotype nor in mice carrying a single copy of the
transgene (R26CT+/-; Cre+). Although we were able to
detect CT-GFP expression by immunohistochemistry in
the brain of these heterozygous mice (R26CT+/-; Cre+)
from P0 to 12 months of age (the oldest age studied),
the formation of Hirano bodies was not detected. These
findings were surprising, since we have consistently
observed the formation of Hirano bodies in cell cultures
within one day of expression of the transgene
[14,20-22].
One explanation for these results is that the level of
CT-GFP expressed in this mouse model is extremely
low. The ubiquitous ROSA26 promoter is relatively
weak and expresses a very low level of transcription of
transgene [34]. Further, a single copy of transgene may
not be enough to induce the formation of Hirano bodies
at this low level of transcription. The increase in level of
CT-GFP between 1 and 6 months of age may promote
the formation of Hirano bodies (Figure 2C). More gen-
erally, the frequency of Hirano bodies found in the neu-
rons of normal individuals as well as subjects with a
number of neurodegenerative diseases including Alzhei-
mer’s disease is known to increase with age [33]. Thus,
although Hirano bodies form within 24 hours after
expression in cultured cells [14,22], other factors may
contribute to the delay of 6 months in formation of Hir-
ano bodies in the brain. Since autophagy and the protea-
some both contribute to the turnover of Hirano bodies
[23], it seems possible that these degradative
mechanisms may contribute to this delay. However, our
findings did not support the hypothesis that autophagy
is induced in these animals and delays the accumulation
of Hirano bodies (Figure 2). Efficient degradation of CT-
GFP by the proteasome [23] or basal levels of autophagy
may be responsible for the significant lag between
expression of the CT-GFP protein and the appearance
of Hirano bodies.
The precise mechanisms that induce formation of Hir-
ano bodies in the brain remain unknown. In prior pub-
lished reports, Hirano bodies are described as large well
ordered structures 10-20 μm in diameter [5,32]. In cul-
tured cells, formation of model Hirano bodies occurs by
aggregation of smaller structures into larger ordered
aggregates [22,37]. The accumulation of smaller ordered
structures into a single aggregate initially gives rise to a
fingerprint appearance in our culture model [22], which
corresponds in appearance to fingerprint inclusions
described previously [38]. We also observed smaller Hir-
ano bodies (~1 μm) in this mouse model (Figure 6).
These findings suggest that Hirano bodies are formed
by a process in which small ordered aggregates form,
coalesce into larger structures, and then rearrange into a
single large ordered array of the type most often
reported in the literature. Recent reports implicate tau
[39], altered forms of VASP [40], and stabilization of
actin filaments [41-43] as factors in the formation of
Hirano bodies. However, the structures formed in these
studies lack the paracrystalline organization of authentic
Hirano bodies. Identification of the critical trigger or
inducer of formation of Hirano bodies in vivo is a signif-
icant challenge for future studies.
While Hirano bodies are known to be associated with
a large number of conditions and diseases including
aging, chronic alcoholism, and neurodegenerative dis-
ease, we know very little regarding the potential effects
of Hirano bodies in promoting and/or modulating the
progression of disease. Actin is a major cytoskeletal pro-
tein in neurons that is involved in many aspects of cell
motility, vesicle transport, and synaptic plasticity. Rear-
rangement of the cytoskeleton has been implicated in
cellular response to stress and development of pathology
in neurodegenerative disease [44]. Our prior studies
show that cultured cells with Hirano bodies grow at
rates comparable to or slightly slower than those of con-
trol cells [20-22]. Further, Hirano bodies modulate tran-
scription dependent on AICD and Fe65 and attenuate
AICD induced cell death in cell cultures [14], suggesting
that Hirano bodies may function as endogenous protec-
tive structures that delay or prevent development of
pathology. The results in the present work reveal that
the presence of Hirano bodies in pyramidal cells in the
hippocampus does not grossly affect the organization or
number of these cells (Figure 4). Homozygous double
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transgenic mice develop Hirano bodies, but remain
healthy and fertile with no apparent behavioral pheno-
types. At the functional level, basal synaptic transmis-
sion following a single stimulus was not significantly
altered (Figure 7A), although short-term synaptic plasti-
city in response to paired-pulse stimulation was drama-
tically shifted from facilitation to depression (Figure 7B).
In addition, late LTP was observed in hippocampal
slices from mice with model Hirano bodies of a magni-
tude that did not differ significantly from that of wild
type mice, whereas the magnitude of early LTP was sig-
nificantly decreased (Figure 8).
There are a number of possible explanations for these
effects of Hirano bodies on synaptic plasticity. First, the
sequestration of actin in Hirano bodies may affect the
diverse roles of the actin cytoskeleton in multiple pre-
and postsynaptic processes [45]. Hirano bodies sequester
a large amount of actin that is assembled in filaments,
resulting in an increase in the level of filamentous actin,
a decrease in unpolymerized actin, and no change in
total cellular actin [20,21]. The facilitation of synaptic
response observed following paired-pulse stimulation is
thought to reflect a presynaptic event related to residual
calcium at the synapse [46]. Following the first stimulus
event, recovery involves not only active transport of cal-
cium, but also trafficking of neurotransmitter-containing
vesicles in order to regenerate a pool of neurotransmit-
ter containing vesicles that is competent for rapid exo-
cytosis and release following elevation of calcium [47].
Since the trafficking of these neurotransmitter contain-
ing vesicles is also modulated by the actin cytoskeleton
[48], the simplest explanation for the observed paired-
pulse depression is a change in vesiclular trafficking due
to the presence of the Hirano body. Another report of
paired-pulse depression in mice that are deficient for
profilin, a potent facilitator of actin assembly, is consis-
tent with this interpretation [49].
Long-term potentiation has two phases, early and late,
both of which are associated with an increase in actin
assembly and only the latter requires protein synthesis
[50-52]. The actin assembly associated with the late
stage of LTP involves an increase in the number and
size of dendritic spines, and growth of the postsynaptic
densities [50,51]. The fact that LTP in Hirano body
mice reaches the magnitude observed in wild type mice
during the last phase (i.e. 3+ hr post induction) demon-
strates that the necessary changes in protein synthesis,
receptor trafficking and distribution, and spine morphol-
ogy have all occurred to support the maintenance of late
LTP. The actin assembly occurring during the early
stage of LTP likely reflects the role of the cytoskeleton
in trafficking of NMDA and AMPA receptors [53-55].
Thus, one likely explanation for the deficiency in early
LTP observed in the R26CT+/+;Cre+ mice is that the
available dynamic actin pool is smaller in neurons with
Hirano bodies, resulting in a delay in the rate of recep-
tor trafficking and in development of the early phase of
LTP. In addition, the alterations in synaptic plasticity in
our transgenic mice may be a consequence of the asso-
ciation with Hirano bodies of synaptic components and/
or modulators including PSD 95 [56] and atypical pro-
tein kinase C isoforms [57]. These potential molecular
explanations of the effects of Hirano bodies on synaptic
plasticity merit additional study.
Future studies of these mice will be required to deter-
mine the behavioral correlates of these changes in
short-term and long-term synaptic plasticity in the hip-
pocampus. The depression of paired-pulse responses
could have a variety of behavioral/physiological results.
One such possibility would be suppression of excitotoxi-
city in animals with Hirano bodies, as excessive gluta-
matergic excitation is proposed to contribute to cell
death and neurodegeneration [58]. With respect to the
effects on long-term plasticity, since LTP reaches nor-
mal levels at the later phase, we predict that some tests
in Hirano body mice will indicate normal capacity for
learning and memory, although deficits related to the
impairment of the early phase of LTP may be signifi-
cant. The behavioral consequences of these diverse
results for these various aspects of synaptic plasticity
remain to be elucidated. Further, studies of neuropathol-
ogy, electrophysiology, and behavior at multiple time
points will allow correlation of results from these indica-
tors during aging and disease progression.
The mouse model for Hirano bodies described here
will be a critical tool for future studies of the role of
Hirano bodies in disease progression. Although some
APP transgenic mouse strains revealed Hirano-like
bodies in the brain, the physiological roles of the Hirano
bodies on AD progression could not be determined
[17-19]. The ability to generate mice that model both
Alzheimer’s pathology and model Hirano bodies should
provide an avenue to determine directly whether Hirano
bodies have either a deleterious or adaptive effect on
Alzheimer’s disease progression. Similarly, crossing
model Hirano body mice with mouse models for other
diseases will permit study of their role in the progres-
sion of the many different conditions with which they
are associated.
Conclusions
We have developed the first transgenic animal model for
experimental studies of Hirano bodies in vivo. The pre-
sence of Hirano bodies in the hippocampus was con-
firmed by H and E staining and by electron microscopy.
Transgenic mice with Hirano bodies appear healthy and
fertile. No abnormalities in the organization and histol-
ogy of the brain were detected. Mice with Hirano bodies
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exhibit distinct alterations in synaptic plasticity. This
mouse model will be valuable for future studies of the
role of Hirano bodies in aging and in progression of
disease.
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